methyl 3-allyl-2-hydroxy-4-methylbenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-allyl-2-hydroxy-4-methylbenzoate
• 英文别名: Methyl 2-hydroxy-3-allyl-4-methylbenzoate；methyl 2-hydroxy-4-methyl-3-prop-2-enylbenzoate
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: WWRFRRUCQNLZBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-allyl-2-hydroxy-4-methylbenzoate 在 四氧化锇 、 N-甲基吗啉氧化物 、 sodium periodate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 13.0h， 以2 g的产率得到methyl 2-hydroxy-4-methyl-3-(2-oxoethyl)benzoate
  参考文献：
  名称：

  C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  公开号：

  EP3404033B1
• 作为产物：
  描述：

  4-甲基水杨酸甲酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 methyl 3-allyl-2-hydroxy-4-methylbenzoate
  参考文献：
  名称：

  C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  公开号：

  EP3404033B1

文献信息

• Dihydrobenzofuran- and chroman-carboxamide derivatives, processes for
  申请人：Laboratoires Delagrange

  公开号：US05006570A1

  公开（公告）日：1991-04-09

  The invention relates to new dihydrobenzofuran- and chroman-carboxamide derivatives of the general formula: ##STR1## in which R and R' are each hydrogen or methyl; n is 1 or 2; m is 1 or 2; Z is either ##STR2## wherein R.sub.1 and R.sub.2 are lower alkyl, or ##STR3## wherein R.sub.3 is alkyl, alkenyl, cycloalkyl-alkyl, cycloalkenyl-alkyl, X is H, NH.sub.2, methoxy, or methyl and Y is H, Cl, cycloalkylmethylsulfonyl, alkylsulfamoyl or alkylsulfonyl and to their pharmacologically acceptable acid addition salts and their optical isomers, to the processes for the preparation thereof and to the use thereof as medicaments, especially as neuroleptics.

  本发明涉及新的二氢苯并呋喃和色满羧酰胺衍生物，其一般式如下：##STR1## 其中R和R'分别为氢或甲基；n为1或2；m为1或2；Z为以下之一：##STR2##其中R1和R2为低级烷基，或##STR3##其中R3为烷基、烯基、环烷基-烷基、环烷烯基-烷基，X为H、NH2、甲氧基或甲基，Y为H、Cl、环烷基甲基磺酰基、烷基磺酰胺基或烷基磺酰基，以及它们的药学上可接受的酸加成盐和其光学异构体，其制备过程和作为药物的用途，特别是作为神经乐剂。
• C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
  申请人：Je II Pharmaceutical Co., Ltd.

  公开号：US10752604B2

  公开（公告）日：2020-08-25

  The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

  本公开涉及具有融合苯基环的 C-糖苷衍生物或其药物可接受盐、制备方法、包含其的药物组合物、其用途以及使用其对 SGLT1 和 SGLT2 进行双重抑制的方法。本公开的一种新型化合物具有对 SGLT1 和 SGLT2 的双重抑制活性，因此可用作糖尿病治疗剂。
• C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same
  申请人：Je Il Pharmaceutical Co., Ltd.

  公开号：US20190002425A1

  公开（公告）日：2019-01-03

  The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.
• US5006570A
  申请人：——

  公开号：US5006570A

  公开（公告）日：1991-04-09
• [EN] C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] DÉRIVÉ DE C-GLUCOSIDE CONTENANT UN CYCLE PHÉNYLE CONDENSÉ OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT<br/>[KO] 융합 페닐 환이 포함된 C-글루코시드 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
  申请人：JE IL PHARMACEUTICAL CO LTD

  公开号：WO2017119700A1

  公开（公告）日：2017-07-13

  본 발명은 융합 페닐 환이 포함된 C-글루코시드 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법, 이를 포함하는 약학적 조성물, 이의 용도 및 이를 이용한 SGLT1 및 SGLT2의 이중 억제 방법에 관한 것이다. 본 발명의 신규 화합물은 SGLT1 및 SGLT2의 이중 억제 활성이 있으므로 당뇨병 치료제로서 유용하게 사용될 수 있다.